Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice

Abstract

Type 2 diabetes (T2D) and Alzheimer’s disease (AD) share several common pathophysiological features. Huperzine A (Hup A), a Lycopodium alkaloid extracted from the Chinese herb moss Huperzia serrata, is a specific and reversible inhibitor of acetylcholinesterase, which is clinically used for the treatment of AD. In this study, we investigated whether Hup A improved the metabolic and cognitive functions in the high fat-induced (HFD) obese mice and genetic ob/ob mice. HFD and ob/ob mice were treated with Hup A (0.1, 0.3 mg · kg−1 · d−1, ig) for 3 months. Body weight was monitored and glucose tolerance tests were performed. Novel object recognition test and Morris water maze assay were conducted to evaluate the cognitive functions. We found that the Hup A treatment had no significant effect on peripheral metabolism of obese mice, whereas Hup A (0.1, mg · kg−1 · d−1) improved both the abilities of object recognition and spatial memory in HFD-fed mice, but not in ob/ob mice. Furthermore, Hup A treatment significantly upregulated the insulin and phosphorylated Akt levels in the cortex of HFD-fed mice, but not ob/ob mice. In addition, Hup A (0.3, mg · kg−1 · d−1) significantly decreased cortical β-secretase (BACE1) expression. In conclusion, these results demonstrate that treatment with Hup A (0.1, mg · kg−1 · d−1) can effectively improve the cognitive functions, at least in diet-induced obese mice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H. The prevalence and progression of mild cognitive impairment among clinic and community populations: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29:1595–608.

  2. 2.

    Sugimoto T, Sakurai T, Ono R, Kimura A, Saji N, Niida S, et al. Epidemiological and clinical significance of cognitive frailty: a mini review. Ageing Res Rev. 2018;44:1–7.

  3. 3.

    Gujral UP, Weber MB, Staimez LR, Narayan KMV. Diabetes among non-overweight individuals: an Emerging Public Health Challenge. Curr Diab Rep. 2018;18:60.

  4. 4.

    Caselli RJ, Beach TG, Yaari R, Reiman EM. Alzheimer’s disease a century later. J Clin Psychiatry. 2006;67:1784–800.

  5. 5.

    Miyoshi K. What is ‘early onset dementia’? Psychogeriatrics. 2009;9:67–72.

  6. 6.

    Plucinska K, Dekeryte R, Koss D, Shearer K, Mody N, Whitfield PD, et al. Neuronal human BACE1 knockin induces systemic diabetes in mice. Diabetologia. 2016;59:1513–23.

  7. 7.

    Zou L, Yang R, Zhang P, Dai Y. The enhancement of amyloid precursor protein and beta-site amyloid cleavage enzyme 1 interaction: amyloid-beta production with aging. Int J Mol Med. 2010;25:401–7.

  8. 8.

    Ham S, Kim TK, Lee S, Tang YP, Im HI. MicroRNA profiling in aging brain of PSEN1/PSEN2 double knockout mice. Mol Neurobiol. 2018;55:5232–42.

  9. 9.

    Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, et al. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J. 2012;441:285–96.

  10. 10.

    Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797–806.

  11. 11.

    Kravitz E, Schmeidler J, Schnaider Beeri M. Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. Endocrinol Metab Clin North Am. 2013;42:489–501.

  12. 12.

    Adam AP. A potential new mechanism linking type II diabetes mellitus and Alzheimer’s disease. Bioessays. 2018;40:e1800061.

  13. 13.

    Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017;124:1431–54.

  14. 14.

    Hassing LB, Dahl AK, Thorvaldsson V, Berg S, Gatz M, Pedersen NL, et al. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int J Obes (Lond). 2009;33:893–8.

  15. 15.

    Alford S, Patel D, Perakakis N, Mantzoros CS. Obesity as a risk factor for Alzheimer’s disease: weighing the evidence. Obes Rev. 2018;19:269–80.

  16. 16.

    Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, Buring JE, et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc. 2008;56:1028–36.

  17. 17.

    Chen F, Dong RR, Zhong KL, Ghosh A, Tang SS, Long Y, et al. Antidiabetic drugs restore abnormal transport of amyloid-beta across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology. 2016;101:123–36.

  18. 18.

    Morris JK, Vidoni ED, Mahnken JD, Montgomery RN, Johnson DK, Thyfault JP, et al. Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. Neurobiol Aging. 2016;39:19–24.

  19. 19.

    Abolhassani N, Leon J, Sheng Z, Oka S, Hamasaki H, Iwaki T, et al. Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative DNA damage in Alzheimer’s disease brain. Mech Ageing Dev. 2017;161:95–104.

  20. 20.

    Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm (Vienna). 1998;105:423–38.

  21. 21.

    Baranowska-Bik A, Bik W. Insulin and brain aging. Prz Menopauzalny. 2017;16:44–6.

  22. 22.

    Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27:1–26.

  23. 23.

    Zhu HF, Yan PW, Wang LJ, Liu YT, Wen J, Zhang Q, et al. Protective properties of Huperzine A through activation Nrf2/ARE-mediated transcriptional response in X-rays radiation-induced NIH3T3 cells. J Cell Biochem. 2018;119:8359–67.

  24. 24.

    Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao. 1999;20:486–90.

  25. 25.

    Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharm Exp Ther. 1999;288:814–9.

  26. 26.

    Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging. 2011;28:439–68.

  27. 27.

    Sheng L, Qu Y, Yan J, Liu GY, Wang WL, Wang YJ, et al. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016;37:994–1001.

  28. 28.

    Mei Z, Zheng P, Tan X, Wang Y, Situ B. Huperzine A alleviates neuroinflammation, oxidative stress and improves cognitive function after repetitive traumatic brain injury. Metab Brain Dis. 2017;32:1861–9.

  29. 29.

    Zhu N, Lin J, Wang K, Wei M, Chen Q, Wang Y. Huperzine A protects neural stem cells against Abeta-induced apoptosis in a neural stem cells and microglia co-culture system. Int J Clin Exp Pathol. 2015;8:6425–33.

  30. 30.

    Tao LX, Huang XT, Chen YT, Tang XC, Zhang HY. Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons. Acta Pharmacol Sin. 2016;37:1391–400.

  31. 31.

    Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals. 2005;14:71–82.

  32. 32.

    Mao XY, Zhou HH, Li X, Liu ZQ. Huperzine A alleviates oxidative glutamate toxicity in hippocampal HT22 cells via activating BDNF/TrkB-dependent PI3K/Akt/mTOR signaling pathway. Cell Mol Neurobiol. 2016;36:915–25.

  33. 33.

    Mao XY, Cao DF, Li X, Yin JY, Wang ZB, Zhang Y, et al. Huperzine A ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Int J Mol Sci. 2014;15:7667–83.

  34. 34.

    Wang Y, Tang XC, Zhang HY. Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. J Neurosci Res. 2012;90:508–17.

  35. 35.

    Molz P, Ellwanger JH, Zenkner FF, Campos D, Pra D, Putzke MT, et al. Recognition memory and DNA damage in undernourished young rats. Acad Bras Cienc. 2016;88:1863–73.

  36. 36.

    Lueptow LM. Novel object recognition test for the investigation of learning and memory in mice. J Vis Exp. 2017;126:e55718.

  37. 37.

    Dong Z, Han H, Li H, Bai Y, Wang W, Tu M, et al. Long-term potentiation decay and memory loss are mediated by AMPAR endocytosis. J Clin Invest. 2015;125:234–47.

  38. 38.

    Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer’s disease model mice. J Vis Exp. 2011;53:2920.

  39. 39.

    Gupta S, Yadav K, Mantri SS, Singhal NK, Ganesh S, Sandhir R. Evidence for compromised insulin signaling and neuronal vulnerability in experimental model of sporadic Alzheimer’s disease. Mol Neurobiol. 2018;55:8916–35.

  40. 40.

    Kasper JM, Milton AJ, Smith AE, Laezza F, Taglialatela G, Hommel JD, et al. Cognitive deficits associated with a high-fat diet and insulin resistance are potentiated by overexpression of ecto-nucleotide pyrophosphatase phosphodiesterase-1. Int J Dev Neurosci. 2018;64:48–53.

  41. 41.

    Lucic I, Rathinaswamy MK, Truebestein L, Hamelin DJ, Burke JE, Leonard TA. Conformational sampling of membranes by Akt controls its activation and inactivation. Proc Natl Acad Sci U S A. 2018;115:e940–e9.

  42. 42.

    Rajasekar N, Dwivedi S, Nath C, Hanif K, Shukla R. Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. Neuropharmacology. 2014;86:337–52.

  43. 43.

    Kamikubo Y, Takasugi N, Niisato K, Hashimoto Y, Sakurai T. Consecutive analysis of BACE1 function on developing and developed neuronal cells. J Alzheimers Dis. 2016;56:641–53.

  44. 44.

    Crunkhorn S. Alzheimer disease: BACE1 inhibitor reduces beta-amyloid production in humans. Nat Rev Drug Discov. 2016;16:18.

  45. 45.

    Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer’s disease. PLoS ONE. 2012;7:e32792.

  46. 46.

    Wang J, Zhang HY, Tang XC. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res. 2010;88:807–15.

  47. 47.

    Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett. 2007;581:596–602.

  48. 48.

    Wang J, Chen F, Zheng P, Deng W, Yuan J, Peng B, et al. Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice. Exp Neurol. 2012;236:79–87.

  49. 49.

    Akintola AA, van Heemst D. Insulin, aging, and the brain: mechanisms and implications. Front Endocrinol (Lausanne). 2015;6:13.

  50. 50.

    Havrankova J, Roth J, Brownstein MJ. Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J Clin Invest. 1979;64:636–42.

  51. 51.

    Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005;16:59–65.

  52. 52.

    Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes. 1999;48:557–63.

  53. 53.

    Rajasekar N, Nath C, Hanif K, Shukla R. Intranasal insulin administration ameliorates streptozotocin (ICV)-induced insulin receptor dysfunction, neuroinflammation, amyloidogenesis, and memory impairment in rats. Mol Neurobiol. 2017;54:6507–22.

  54. 54.

    Nguyen TTL, Chan LC, Borreginne K, Kale RP, Hu C, Tye SJ. A review of brain insulin signaling in mood disorders: from biomarker to clinical target. Neurosci Biobehav Rev. 2018;92:7–15.

  55. 55.

    Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, et al. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis. 2015;47:715–28.

  56. 56.

    Maimaiti S, Anderson KL, DeMoll C, Brewer LD, Rauh BA, Gant JC, et al. Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J Gerontol A Biol Sci Med Sci. 2016;71:30–9.

  57. 57.

    Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, et al. High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS ONE. 2015;10:e0128274.

  58. 58.

    Gralle M. The neuronal insulin receptor in its environment. J Neurochem. 2017;140:359–67.

  59. 59.

    Cheng X, He P, Lee T, Yao H, Li R, Shen Y. High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol. 2014;184:141–7.

  60. 60.

    Sadleir KR, Eimer WA, Cole SL, Vassar R. Abeta reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener. 2015;10:1. https://doi.org/10.1186/1750-1326-10-1.

  61. 61.

    Huse JT, Byant D, Yang Y, Pijak DS, D’Souza I, Lah JJ, et al. Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation. J Biol Chem. 2003;278:17141–9.

  62. 62.

    Vattemi G, Engel WK, McFerrin J, Pastorino L, Buxbaum JD, Askanas V. BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol. 2003;179:150–8.

  63. 63.

    Zhang T, Pan BS, Zhao B, Zhang LM, Huang YL, Sun FY. Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-secretase activation and beta-amyloid generation in rat brains. Neuroscience. 2009;161:1045–56.

  64. 64.

    MacPherson RE, Baumeister P, Peppler WT, Wright DC, Little JP. Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice. J Appl Physiol. 2015;119:1097–104.

  65. 65.

    Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007;56:1817–24.

  66. 66.

    Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett. 2004;360:21–4.

  67. 67.

    Shi Q, Fu J, Ge D, He Y, Ran J, Liu Z, et al. Huperzine A ameliorates cognitive deficits and oxidative stress in the hippocampus of rats exposed to acute hypobaric hypoxia. Neurochem Res. 2012;37:2042–52.

  68. 68.

    Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015;18:800–6.

  69. 69.

    Chen G, Chen KS, Kobayashi D, Barbour R, Motter R, Games D, et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci. 2007;27:2654–62.

  70. 70.

    Denver P, McClean PL. Distinguishing normal brain aging from the development of Alzheimer’s disease: inflammation, insulin signaling and cognition. Neural Regen Res. 2018;13:1719–30.

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81871222, 81570763, and 81270947 to XQX), the Fundamental Science and Advanced Technology Research of Chongqing (Major Project, CSTC2015jcyjB0146), and the National Program on Key Basic Research Project of China (973 Program, 2012CB517505, to XQX).

Author contributions

HYW and XQX designed the research; HYW, MW, and JLD performed the research; HYW and MW analyzed the data; JBL and YXS contributed the materials; and HYW and XQX wrote the paper.

Author information

Correspondence to Xiao-qiu Xiao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • obesity
  • huperzine A
  • cognitive dysfunction
  • neuronal insulin signaling